PVLA
Palvella Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 21.37K | New | $256,452 | 0.0% | New | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 14.27K | New | $171,287 | 0.0% | New | 1 | SEC ↗ ×2 |
| 3 | Citadel Advisors ✦ | 10.41K | New | $124,896 | 0.0% | New | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Renaissance Technologies | $256,452 | 0.0% |
| Geode Capital Management | $171,287 | 0.0% |
| Citadel Advisors | $124,896 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 181 holders, 13.20M shares, $1.59B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 476 sh · $57,663
Director · 505 sh · $63,910
Director · 597 sh · $74,820
Director · 920 sh · $114,416
Director · 2.60K sh · $321,046
Director · 2.07K sh · $254,058
Director · 1.64K sh · $212,455
Director · 922 sh · $123,292
Director · 579 sh · $76,662
Director · 1.03K sh · $136,092
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology